ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly December 30, 2025
Oncodesign Precision Medicine and Navigo Proteins announce the end of their collaboration in the development of radiotheranostics December 30, 2025
GMP Manufacturing of AKTX-101 ADC Program Initiated to Support Ph 1 First-in-Human Clinical Trial December 30, 2025
Pidnarulex (CX-5461) – Enhertu combo to be evaluated in Ph 1b trial in HER2-positive and HER2-low solid tumors and breast cancer patients December 30, 2025
Caris Life Sciences Announces Collaboration with Genentech to Discover Novel Therapeutic Targets in Cancers with High Unmet Clinical Need December 22, 2025
Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with BMS to Discover and Develop Next-Gen Multi-Specific Antibodies December 22, 2025
Orum Therapeutics Secures ~US$100M to Accelerate Development of Leading Degrader ADC Programs to Treat Serious Diseases December 22, 2025
University of Chicago Extends Collaboration with AbbVie to Advance Clinical Research and Patient Outcomes in Oncology December 22, 2025
CTA submitted in the UK for First-in-Human Study of ZI-MA4-1 (ZIMA-101) for Solid Tumors December 22, 2025
IND Application to Initiate a Ph 1 Trial of ABP-102/CT-P72 for HER2-positive Cancers submitted to the US FDA December 22, 2025
FDA approves IND to start a Ph 1/2 trial for PM54 + immunotherapy combo in advanced solid tumors December 22, 2025
Oxford BioTherapeutics Enters into a Strategic Collaboration with GSK to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer December 15, 2025
Crescent Biopharma Announces Partnership with Kelun-Biotech and $185M Private Placement for Next Gen Therapeutics for Solid Tumors December 9, 2025
First US Commercial Sale of KOMZIFTI™ Triggers $135M Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin December 9, 2025
Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of Eftilagimod Alfa December 9, 2025
Takeda Announces Closing of Strategic Partnership with Innovent Biologics for Next-Gen Investigational Oncology Medicines December 9, 2025
First Patient Dosed in Ph 1/2 Trial of CRN09682 for the Treatment of NETs and Other Somatostatin Receptor 2-Expressing Tumors December 9, 2025
Additional Positive LP-184 Ph 1a Results Reported Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients December 9, 2025
Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours December 2, 2025
